OXERVATE (cenegermin-bkbj)
OPHTHALMIC HUMAN NERVE GROWTH FACTOR (HNGF) · NEUROTROPHIC KERATITIS
DOMPE US, INC
Drug class
Ophthalmic Human Nerve Growth Factor (hNGF)
Ophthalmic human nerve growth factor (hNGF)—more formally designated in clinical pharmacology and regulatory classifications as recombinant human nerve growth factor (rhNGF) ophthalmic therapy—is a specialized biologic class represented clinically by cenegermin. Read more about Ophthalmic Human Nerve Growth Factor (hNGF)
1 drugs in this class 1 manufacturers
Drugs in Ophthalmic Human Nerve Growth Factor (hNGF)
Filter & compare in the drug finder →
Opens the drug finder with Ophthalmic Human Nerve Growth Factor (hNGF) preselected. Add indication or manufacturer filters there.
Ophthalmic human nerve growth factor (hNGF)—more formally designated in clinical pharmacology and regulatory classifications as recombinant human nerve growth factor (rhNGF) ophthalmic therapy—is a specialized biologic class represented clinically by cenegermin.
Agents in this class mimic endogenous human nerve growth factor, binding to high-affinity tropomyosin receptor kinase A (TrkA) and low-affinity p75 neurotrophin receptors on corneal epithelial cells and sensory nerves.
Through this mechanism, the class stimulates corneal nerve survival, neurite outgrowth, epithelial cell proliferation, and tear production to restore ocular surface integrity.
Its principal therapeutic indication is neurotrophic keratitis, a rare degenerative corneal condition resulting from trigeminal nerve impairment.
-
dompe.com
Ophthalmic human nerve growth factor (hNGF)—more formally designated in clinical pharmacology and regulatory classifications as recombinant human nerve growth factor (rhNGF) ophthalmic therapy—is a specialized biologic class represented clinically by cenegermin Its principal therapeutic indication is neurotrophic keratitis, a rare degenerative corneal condition resulting from trigeminal nerve impairment
-
nih.gov
Ophthalmic human nerve growth factor (hNGF)—more formally designated in clinical pharmacology and regulatory classifications as recombinant human nerve growth factor (rhNGF) ophthalmic therapy—is a specialized biologic class represented clinically by cenegermin Its principal therapeutic indication is neurotrophic keratitis, a rare degenerative corneal condition resulting from trigeminal nerve impairment
-
nih.gov
Ophthalmic human nerve growth factor (hNGF)—more formally designated in clinical pharmacology and regulatory classifications as recombinant human nerve growth factor (rhNGF) ophthalmic therapy—is a specialized biologic class represented clinically by cenegermin
-
optometrytimes.com
Agents in this class mimic endogenous human nerve growth factor, binding to high-affinity tropomyosin receptor kinase A (TrkA) and low-affinity p75 neurotrophin receptors on corneal epithelial cells and sensory nerves Through this mechanism, the class stimulates corneal nerve survival, neurite outgrowth, epithelial cell proliferation, and tear production to restore ocular surface integrity
-
drugbank.com
Agents in this class mimic endogenous human nerve growth factor, binding to high-affinity tropomyosin receptor kinase A (TrkA) and low-affinity p75 neurotrophin receptors on corneal epithelial cells and sensory nerves Through this mechanism, the class stimulates corneal nerve survival, neurite outgrowth, epithelial cell proliferation, and tear production to restore ocular surface integrity
-
bcbsfl.com
Through this mechanism, the class stimulates corneal nerve survival, neurite outgrowth, epithelial cell proliferation, and tear production to restore ocular surface integrity Its principal therapeutic indication is neurotrophic keratitis, a rare degenerative corneal condition resulting from trigeminal nerve impairment
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.